- Late-breaking poster presentation to highlight updated Phase 1 clinical data of PC14586, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors that have a TP53 Y220C mutation
- Company to host KOL webinar on October 12, 2023 to review data and provide regulatory update
PRINCETON, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that updated Phase 1 clinical data from its ongoing Phase 1/2 PYNNACLE study of PC14586 will be presented in a late-breaking poster session at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 11-15, 2023, in Boston, Massachusetts.
"We are excited to share updated data from our ongoing Phase 1/2 PYNNACLE clinical trial of PC14586 at this year's AACR-NCI-EORTC conference," said David Mack, Ph.D., President and Chief Executive Officer of PMV Pharma. "We look forward to presenting and continuing to progress the PC14586 development program."
PMV will host a KOL webinar for the investment community on Thursday, October 12, 2023 at 4:00 PM ET to review the data and to provide a regulatory update. The webinar will feature presentations by Aparna Parikh, M.D. M.S., Director of the Global Cancer Care Program at Mass General Hospital Cancer Center, and by PMV management.
Poster presentation details: | |
Title: | Updated Phase 1 results from the PYNNACLE Phase 1/2 study of PC14586, a selective p53 reactivator, in patients with advanced solid tumors harboring a TP53 Y220C mutation |
Session Date and Time: | 12.30 PM – 4:00 PM ET on Thursday, October 12, 2023 |
Session Title: | Poster ... |